Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 16/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10121299 | 0.88 | PDE3B (0.44) | PDE3BPDE3AHRH3SLC6A4 | |
| SCHEMBL18466064 | 0.86 | PDE3B (0.55) | PDE3BPDE3AHRH3SLC5A7 | |
| SCHEMBL15829971 | 0.84 | SLC6A4 (0.50) | HRH3SLC6A4ADORA2A | |
| SCHEMBL19171657 | 0.82 | HRH3 (0.55) | HRH3SLC6A4 | |
| SCHEMBL22098608 | 0.82 | HRH3 (0.58) | HRH3SLC6A4 | |
| SCHEMBL2737409 | 0.82 | HRH3 (0.58) | HRH3SLC6A4 | |
| SCHEMBL16217378 | 0.81 | HRH3 (0.47) | HRH3SLC6A4ADORA2A | |
| SCHEMBL12766191 | 0.80 | PDE3B (0.46) | PDE3BPDE3ASLC6A4 | |
| SCHEMBL19633416 | 0.79 | RORC (0.48) | PDE3BPDE3AHRH3 | |
| SCHEMBL20252292 | 0.79 | PDE3B (0.48) | PDE3BPDE3AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10307413-B2 | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180098987-A1 | PRMT5 Inhibitors and Uses Thereof | Epizyme, Inc. (US) | 2018-04-12 | — | — | US | disclosed |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180098987-A1 | PRMT5 Inhibitors and Uses Thereof | PRMT5, PRMT1, PRMT6 | PDE3B 324/4885PDE3A 335/4885HRH3 1460/4885 |
| US-10307413-B2 | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT3 | PDE3B 298/4885PDE3A 354/4885HRH3 629/4885 |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | PDE3B 298/4885PDE3A 354/4885HRH3 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.